Navigation Links
Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids

t, no statistically significant changes in endometrial thickness were detected among the women who underwent ultrasound measurements of endometrial thickness at various time points. This study uses an endometrial thickness cut-off of 14mm after three months of dosing to determine whether or not a woman is allowed to proceed into an ongoing open label study. For those patients that were evaluated 9 patients at the 12.5 mg dose and 4 patients at the 25 mg dose exhibited an endometrium greater than 14 mm compared to 6 patients on placebo. An expert panel of pathologists will review all of the biopsies using the WHO criteria in addition to a specific classification created for the analysis of the histology in this study. Fifty-eight patients have rolled into a one-year open label extension study.

All reproductive hormones remained in the normal range and there is no indication of bone loss using evaluating markers of bone resorption. In fact, there was a statistically significant increase in osteocalcin in the two Proellex groups. Osteocalcin is a marker associated with bone formation. In addition there was no change in urinary 24 hour cortisol excretion or serum adrenocorticotropic hormone (ACTH) indicating a lack of antiglucocorticoid activity at the receptor level.

Both doses of Proellex were well tolerated. The number of adverse events judged to be treatment related by the investigators in the Proellex 12.5 and 25 mg treatment groups were similar in incidence to placebo. The exception was the occurrence of amenorrhea (an expected drug effect) in 78.6% and hot flashes in 16.7% of all Proellex treated patients, respectively. The hot flashes were not dose dependent. The severity of the hot flashes was generally mild to moderate as were the vast majority of the other adverse events. On average, there were no clinically significant changes in other laboratory measurements of safety including liver enzymes.

"We are very pleased with these results," co
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:11/21/2014)... CORONA, Calif. and VIENNA, Va. ... an innovative in-home care provider that operates in ... with BeClose, a leading provider of remote caregiving technology. Alta ... new and existing client receiving homecare services. ... believe this technology is the key to providing the ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... DUBLIN, October 18, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... the PRECiSE 3 (P3) open label extension study for ... maintenance trial for an anti-TNF in Crohn,s disease, will ... the American College of Gastroenterology (ACG), taking place in ... efficacy data from the PRECiSE 4 (P4) clinical trial ...
Cached Medicine Technology:Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 2Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 3Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 4Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 5Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 6Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 2UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 3UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 4UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 5UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 6UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 8UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 9UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 10UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 11
(Date:11/23/2014)... 2014 Locks-Magnetic.com, a notable magnetic locks ... all the new products are available at low rates ... is proud of the new emergency doors. The emergency ... customers can choose from several colors. All of the ... emergency door release is not as easy as many ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... Church, VA (PRWEB) November 23, 2014 ... TV Have in Common, **FDAnews On-Demand Webinar**, Dec. 11, ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional activities ... , Now they're looking at websites, Twitter, ... Mark the calendar for Thursday, Dec. 11, for On-Demand ...
(Date:11/23/2014)... Salt Lake City, Utah (PRWEB) November 23, 2014 ... in individual health insurance reimbursement for small businesses, ... the new book, The End of Employer-Provided Health ... employer-provided health insurance is the greatest financial risk ... greatest challenge facing U.S. employers, small and large, ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 PrettyTailor ... website with a new big promotion. Customers can buy ... detailed information, customers can visit its website. , As ... apparel and occasion dresses. It mainly provides four types ... bride dresses and flower girl dresses. It also provides ...
Breaking Medicine News(10 mins):Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2
... , ... proceeds from its sales to facilitate a speedy recovery from one of the world’s worst ... established to help in the rebuilding of Haiti. MBMI hopes that this initiative will inspire ... ...
... blood test in office, not home tests , THURSDAY, ... proper use of a colorectal cancer screening method called the ... from the U.S. Centers for Disease Control and Prevention surveyed ... them order or perform an in-office fecal occult blood test ...
... researchers from Georgetown University,s Institute for Reproductive Health to ... by a growing number of women to help plan ... wish to become pregnant are unsuccessful because they do ... American Infertility Association. CycleBeads is a fertility management aid ...
... ... for Healthcare Conference, taking place in Houston, TX April 19, 20 and 21, 2010. ... session, "Next Practices" and Best Practices in Learning and Development at Kaiser Permanente. ... Cambridge, MA ...
... more minutes to fall asleep , THURSDAY, April 15 (HealthDay ... well if he indulges in a violent video game right before ... teens who played the popular video game "Call of Duty 4: ... who watched a documentary. , A report on the finding appears ...
... ... celebrating a one-of-a-kind event with the Grand Opening of its new location in ... author Jacqueline Wilson, will be spilling the best kept dog training secrets and ... pet services and products. Guests and their pets will enjoy gourmet foods and ...
Cached Medicine News:Health News:MBMI Steel Buildings is Saving Haiti One Building at a Time 2Health News:Many Doctors Not Using Colon Cancer Test Properly 2Health News:Getting the bead on conception 2Health News:Getting the bead on conception 3Health News:Interaction Associates to Sponsor HCI Talent Management for Health Care Conference 2Health News:Interaction Associates to Sponsor HCI Talent Management for Health Care Conference 3Health News:Video Games Before Bed May Not Shortchange Slumber 2Health News:Video Games Before Bed May Not Shortchange Slumber 3Health News:Shi Shi Pet Boutique's Open House Happy Hour Benefiting 'Brooke's Lucky Dog Rescue' Saturday April 24, 2010 4:00pm - 8:00pm 2
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Medicine Products: